Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

New Management Strategies in Heart Failure.

Circulation research - 5 Feb 2016

Owens Anjali Tiku, Brozena Susan C, Jessup Mariell

Abstract excerpt

Despite >100 clinical trials, only 2 new drugs had been approved by the US Food and Drug Administration for the treatment of chronic heart failure in more than a decade: the aldosterone antagonist eplerenone in 2003 and a fixed dose combination of hydralazine-isosorbide dinitrate in 2005. In contrast, 2015 has witnessed the Food and Drug Administration approval of 2 new drugs, both for the treatment of chronic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cardiovascular Agents
Share to Drug Combinations
Share to Heart Failure

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Phenotype

Share to Recovery of Function

Share to Treatment Outcome

Source

Identifiers

PMID: 26846642
DOI: 10.1161/CIRCRESAHA.115.306567

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

New Management Strategies in Heart Failure.PMID 26846642Read ↗

Mechanisms of current therapeutic strategies for heart failure: more questions than answers?Semantic proximity Read ↗

Recent advances in the treatment of chronic heart failureSemantic proximity Read ↗

A Review of Multimodal Treatment Approach in Hypertrophic CardiomyopathySemantic proximity Read ↗

The cardiac enigma: current conundrums in heart failure researchSemantic proximity Read ↗

Medical management of hypertrophic cardiomyopathy.Semantic proximity Read ↗

Sacubitril/Valsartan as a Therapeutic Tool Across the Range of Heart Failure Phenotypes and Ejection Fraction SpectrumSemantic proximity Read ↗

Towards precision medicine in heart failureSemantic proximity Read ↗

Novel Basic Science Insights to Improve the Management of Heart Failure: Review of the Working Group on Cellular and Molecular Biology of the Heart of the Italian Society of Cardiology.Semantic proximity Read ↗

β₃-Adrenergic Signaling in Heart Failure: A Stage-Dependent Double-Edged SwordSemantic proximity Read ↗

Primary heart failure with preserved ejection fraction: The intertwined pathophysiology and treatment of some of the most relevant phenotypes.Semantic proximity Read ↗

Treatment strategies for the prevention of heart failure.Semantic proximity Read ↗

Heart Failure in the Molecular Era: Redefining Our Understanding of Disease Mechanisms and PerspectivesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.